This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Medical Stocks to Consider as Markets Take a Breather
by Shaun Pruitt
These top medical stocks may be able to provide defensive safety after President Trump's tariff hikes and July's unfavorable jobs report led to a market selloff.
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
by Kinjel Shah
JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.
Buy 5 Wide Moat Stocks to Enhance Your Portfolio Returns
by Nalak Das
Boost your portfolio with ADBE, DIS, INTU, ROL and JNJ as these five wide moat stocks poised for growth and strong returns.
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
by Zacks Equity Research
TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
by Zacks Equity Research
ABBV tops Q2 forecasts and lifts 2025 EPS outlook as Rinvoq and Skyrizi drive growth amid Humira's decline.
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
by Zacks Equity Research
GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.
The Zacks Analyst Blog Highlights Broadcom, Berkshire Hathaway, Johnson & Johnson, Oil-Dri Corp. of America and Park Aerospace
by Zacks Equity Research
Broadcom, Berkshire Hathaway, and J&J headline a strong slate of stocks, with rising momentum in AI, insurance, and pharma growth drivers.
Top Analyst Reports for Broadcom, Berkshire Hathaway & Johnson & Johnson
by Mark Vickery
Broadcom gains on AI chip strength and VMware synergy, while JNJ and BRK.B ride momentum despite looming headwinds.
Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?
by Sundeep Ganoria
ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.
Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
J&J Innovative Medicine Unit Shines Again in Q2: Will This Continue?
by Kinjel Shah
JNJ's Innovative Medicine unit posts solid Q2 growth despite Stelara's LOE, powered by Darzalex, Tremfya, Erleada and new drugs.
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
by Ekta Bagri
Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
by Zacks Equity Research
Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures
by Zacks Equity Research
AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.
How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?
by Sundeep Ganoria
ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
VTRS Down on Late-Stage Study Failure of Eye Disease Drug
by Zacks Equity Research
VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
by Kinjel Shah
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
by Kinjel Shah
JNJ jumps over 6% on Q2 earnings beat and full-year guidance increase, driven by strong pharma sales and improved MedTech sales.
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
by Kinjel Shah
JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook
by Sweta Killa
IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.
Company News for Jul 17, 2025
by Zacks Equity Research
Companies in The News Are: JNJ,GS,PGR,FHN
Novartis Beats on Q2 Earnings and Sales, CFO Retires, Stock Down
by Zacks Equity Research
NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.